EN DE
STOCK COMPARISON

AbbVie vs Amgen: Fair Value & Quality

Both stocks run through our valuation models. Here is how AbbVie (ABBV) and Amgen (AMGN) compare, as of Sep 6, 2026.

As of Sep 6, 2026, Fair Value Calculator sees Amgen as the less overvalued of the two: AbbVie trades at $256 versus a fair value of $67.72 (-74%), while Amgen trades at $437 versus $252 (-42%).
AbbVie
ABBV · USD · Health Care
-74%
upside to fair value
overvalued
Price$256
Fair Value$67.72
Quality74/100
Amgen
AMGN · USD · Health Care
-42%
upside to fair value
overvalued
Price$437
Fair Value$252
Quality63/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AbbVieAmgen
Valuation
118.9×P/E (TTM)25.3×
7.16×P/S (TTM)5.27×
—P/B22.65×
16.8×EV/EBITDA14.0×
0.40×PEG2.02×
−73.6%Fair value upside−42.4%
2.6%Dividend yield2.2%
$6.74Dividend per share$9.66
Profitability
32%Operating margin34%
0.83×EBIT margin trend (5Y)0.81×
62%Return on equity101%
10%Return on assets8%
Growth
12%Revenue growth (YoY)6%
1.8%Avg. growth/yr (3Y)11.8%
6.0%Avg. growth/yr (5Y)7.6%
−6.5%Value creation/yr+2.0%
Balance & size
6.9×Interest coverage (EBIT/interest)3.9×
—Debt / equity5.78×
$449BMarket cap$196B
mixedGrowth qualityhealthy

Amgen leads: 5 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

AbbVieof which business quality 68 · market factors 72 Amgenof which business quality 60 · market factors 86
ProfitabilityMargins and returns on capital today
39
64
Quality GrowthAre margins and returns improving?
58
79
CashflowEarnings quality: real cash, not paper profit
99
78
Fin. StrengthBalance sheet, leverage, solvency risk
47
20
InvestmentDisciplined investing over empire-building
100
42
Low VolatilityCalm price path (market factor)
87
86
MomentumPrice trend over the last 3–12 months (market factor)
59
78
52W MomentumDistance to the 52-week high (market factor)
77
100
Net IssuanceBuybacks instead of dilution
82
81

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAbbViePrice $256AmgenPrice $437
DCF Models-54%below the price$117-37%below the price$275
Earnings-Based-83%below the price$42.53-65%below the price$151
Dividend Discount-51%below the price$126-62%below the price$167
Multiples-71%below the price$73.45-43%below the price$249
Asset-Basedn/a-98%below the price$10.75
Growth DCF-41%below the price$151-51%below the price$214
Economic Profit-57%below the price$111-70%below the price$129
Growth Earnings-84%below the price$40.81-40%below the price$261
Minimum-84%below the price$40.81-98%below the price$10.75
Maximum-41%below the price$151-37%below the price$275
Median-57%below the price$111-56%below the price$190
Geometric mean-67%below the price$84.83-68%below the price$138

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

AbbVie: 23 of 23 models see the stock below the current price.

Amgen: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

AbbVie
Bear $39.47Fair Value $67.72Bull $98.87
$256 = current price (white tick)
Amgen
Bear $135Fair Value $252Bull $340
$437 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

AbbVie · Health Care

Quality score74 · Top 25%
Fair value upside-74% · bottom 25%

Amgen · Health Care

Quality score63 · Top 25%
Fair value upside-42% · below median

Bottom line

As of Sep 6, 2026, Fair Value Calculator sees Amgen as the less overvalued of the two: AbbVie trades at $256 versus a fair value of $67.72 (-74%), while Amgen trades at $437 versus $252 (-42%).

AbbVie has the higher quality score (74/100).

See the full analysis →
AbbVie · Amgen

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to AbbVie

AbbVie vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Amgen

Amgen vs UnitedHealth GroupAstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.